mci 9038 has been researched along with Cirrhosis, Liver in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Copple, BL; Cui, W; Kassel, KM; Luyendyk, JP; Sullivan, BP | 1 |
2 other study(ies) available for mci 9038 and Cirrhosis, Liver
| Article | Year |
|---|---|
Situational Awareness and Patient Safety.
Topics: Adult; Antiphospholipid Syndrome; Antithrombins; Arginine; Awareness; Female; Gastrointestinal Hemorrhage; Humans; Liver Cirrhosis; Male; Medication Errors; Middle Aged; Occult Blood; Patient Safety; Pipecolic Acids; Sulfonamides | 2017 |
Therapeutic administration of the direct thrombin inhibitor argatroban reduces hepatic inflammation in mice with established fatty liver disease.
Topics: Animals; Arginine; Chemokine CCL2; Chemokine CXCL2; Collagen; Diet; Fatty Liver; Feeding Behavior; Gene Expression Regulation; Inflammation; Intercellular Adhesion Molecule-1; Lipid Metabolism; Lipids; Liver; Liver Cirrhosis; Macrophages; Male; Mice; Mice, Inbred C57BL; Neutrophils; Pipecolic Acids; Receptors, LDL; RNA, Messenger; Sulfonamides; Thrombin; Weight Gain | 2012 |